Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Hasan Arshad, MBBS DM FRCP 44 23 8120 5232
p.turner@imperial.ac.uk


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Using Commonly Available Food Products To Treat Food Allergy

Using Commonly Available Food Products To Treat Food Allergy

Recruiting

Open to: ALL

Age: 3.0 - 23.0

Medical Conditions

Hypersensitivity
Food Hypersensitivity
Peanut Hypersensitivity
Milk Hypersensitivity


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Food allergy affects 1 in 30 children, and is the commonest trigger for life-threatening reactions (anaphylaxis) in this age group. It is a major public health issue, with practical implications for industry, education and healthcare systems. Oral immunotherapy (OIT) is an emerging treatment option, where small, increasing doses of a food allergen are used to cause "desensitisation", so food-allergic individuals no longer have symptoms when exposed to the trigger food. However, frequent allergic reactions during OIT (including anaphylaxis) are common, and can lead to patients having to stop treatment. In addition, food-allergic children usually dislike the taste of the food they are allergic too, which affects compliance and treatment success. There is a lack of longer-term data to inform cost-effectiveness analyses for OIT.

The NATASHA study will recruit young people from age 6+ years with IgE-mediated peanut allergy, and young people aged 3+ years with IgE-mediated allergy to cow's milk, who will undergo oral immunotherapy for these allergens using real-world foods (taken carefully according to a standardised protocol under medical supervision). In addition to assessing efficacy and safety outcomes, we will also collect longer-term data to evaluate cost-effectiveness in the UK setting.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jan 2023 Aug 2025

INTERVENTIONAL

Intervention Type : OTHER
Intervention Description : Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol

Intervention Arm Group : Oral Immunotherapy, in-hospital supervision for updosing;Oral Immunotherapy, virtual supervision for updosing;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University Hospital Southampton NHS Foundation Trust
    Southampton
  • Sheffield Children's Hospital NHS Foundation Trust
    Sheffield
  • Imperial College Healthcare NHS Trust
    London
  • University of Hospitals of Leicester NHS Trust
    Leicester
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle

Hasan Arshad, MBBS DM FRCP 44 23 8120 5232
p.turner@imperial.ac.uk



The study is sponsored by University of Southampton and is in collaboration with Imperial College London; Natasha Allergy Research Foundation.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05503446
Last updated 06 June 2023

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.